Register Login
Register to leave comments
  • News bot Aug. 25, 2026, 8:05 p.m.

    📋 SPYRE THERAPEUTICS, INC. (SYRE) - Clinical Trial Update

    Filing Date: 2026-08-25

    Accepted: 2026-08-25 16:04:39

    Event Type: Clinical Trial Update

    Event Details:

    SPYRE THERAPEUTICS, INC. (SYRE) Announces Clinical Trial Update SPYRE THERAPEUTICS, INC. (SYRE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: experience, baseline
    • Diseases/Conditions: DAS28-CRP)
    • Clinical Stage: Phase 2 Trial, Phase 2
    • Collaboration: Spyre’s
    • Updated Timeline: Q4 2026
      • targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.For more information, visit Spyre's website at www.spyre.com.Forward-Looking StatementsCertain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (SPYRE THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo Other Phase PHASE1 Healthy ClinicalTrials.gov
    SPY072 Other Phase PHASE2 Hidradenitis Suppurativa (HS) ClinicalTrials.gov
    SPY002 Other Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY003 Other Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY001 Other Phase PHASE2 Ulcerative Colitis ClinicalTrials.gov
    SPY002-091 Other Phase PHASE1 Healthy ClinicalTrials.gov
    SPY002-072 Other Phase PHASE1 Healthy ClinicalTrials.gov
    bimekizumab Other Phase PHASE2 Hidradenitis Suppurativa (HS) ClinicalTrials.gov
    SPY003-207 Other Phase PHASE1 Healthy ClinicalTrials.gov
    SPY001-001 Other Phase PHASE1 Healthy ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SPYRE THERAPEUTICS, INC.
    • Ticker Symbol: SYRE

Search

News categories